Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission
暂无分享,去创建一个
Elaine Tan Su Yin | He Huang | G. Wei | Yiyun Wang | Yong-xian Hu | A. Jin | Li Yang | Linqin Wang | Ruimin Hong | Houli Zhao | Cheng Zu | Y. Zeng | E. T. S. Yin
[1] Depei Wu,et al. Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement , 2021, Frontiers in Immunology.
[2] Faiza Manji,et al. Cauda Equina Syndrome as the Initial Presentation of Concurrent Plasmacytoma and Multiple Myeloma , 2021, Cureus.
[3] Jinhui Wang,et al. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma , 2020, Cancer Immunology Research.
[4] Philip Egan,et al. Multiple myeloma with central nervous system relapse , 2020, Haematologica.
[5] H. Hinson,et al. Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment , 2019, Current Treatment Options in Neurology.
[6] A. Hottinger,et al. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy , 2019, Current opinion in neurology.
[7] Weiss,et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. , 2019, The Journal of clinical investigation.
[8] Yuan-fang Liu,et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma , 2019, Proceedings of the National Academy of Sciences.
[9] B. Lei,et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma , 2018, Journal of Hematology & Oncology.
[10] Michael L. Wang,et al. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[12] Yi-Bin Chen,et al. Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. , 2017, The New England journal of medicine.
[13] D. Dingli,et al. Myelomatous Involvement of the Central Nervous System. , 2016, Clinical lymphoma, myeloma & leukemia.
[14] Syed Abbas Ali,et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. , 2016, Blood.
[15] S. Rosenberg,et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Heimfeld,et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.
[17] He Huang,et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy , 2016, Journal of Hematology & Oncology.
[18] Daniel Li,et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.
[19] S. Lonial,et al. Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice , 2016, American journal of hematology.
[20] David L. Porter,et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.
[21] Seth M Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[22] B. Barlogie,et al. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma. , 2014, Clinical lymphoma, myeloma & leukemia.
[23] D. Rossi,et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients , 2012, Cancer.
[24] D. Biesma,et al. Central nervous system myelomatosis: review of the literature , 2007, European journal of haematology.
[25] P. Hwu,et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.
[26] A. R.,et al. Review of literature , 1960, American Potato Journal.